Mitomycine Accord (Mitomycin)

Mitomycin is reduced inside cancer cells to generate reactive species that create covalent cross‑links between DNA strands. These cross‑links block DNA replication and transcription, leading to programmed cell death of rapidly dividing tumour cells.

The dosage of Mitomycine Accord is individualized. A qualified prescriber determines the amount, infusion rate, and treatment schedule based on the patient’s cancer type, stage, renal function and overall health.

Safety data for mitomycin in pregnancy and lactation are limited. It is generally contraindicated because of potential fetal toxicity and the risk of drug transfer through breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Mitomycine Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Mitomycin differs from many alkylating agents by forming DNA cross‑links after intracellular reduction, giving it activity against tumours resistant to standard alkylators. Compared with agents such as cisplatin, mitomycin often has a distinct toxicity profile, with higher risks of pulmonary and renal effects but lower ototoxicity.

Mitomycine Accord should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to use, the solution should be inspected for particulate matter and administered by trained medical personnel in a controlled clinical setting.

The product is supplied for intravenous infusion. It is typically diluted in an appropriate carrier solution and infused over a prescribed period, often ranging from 30 minutes to several hours, depending on the treatment protocol and patient tolerance.

Key serious risks include pulmonary fibrosis, severe renal impairment, hemolytic‑uremic syndrome, and life‑threatening allergic reactions. Patients should be monitored closely for respiratory symptoms, changes in kidney function, blood pressure spikes, and any signs of severe hypersensitivity.

Mitomycine Accord should be avoided in individuals with known hypersensitivity to mitomycin or related compounds, in patients with severe pre‑existing pulmonary or renal disease, and in those who are pregnant or breastfeeding unless no safer alternative exists.